While in some studies, high numbers of tumor-infiltrating lymphocytes (TILs) have been associated with an increased efficacy of trastuzumab in early HER2 + breast cancer [4] also contrasting results have been reported [5], and thus it is important to understand the interplay between different immune cells in the tumor microenvironment. This evidence concerns the gene ERBB2 and breast cancer.